Evidence map›Paper›PMID 31045830›Full record

ArticleMedicine2019

Efficacy and safety of Soshiho-tang in patients with atopic dermatitis and gastrointestinal disorders: Study protocol for a double-blind, randomized, and placebo-controlled clinical trial.

Su-Jin Kang, Eun-Heui Jo, Geum-Jin Yang, Yu-Hwa Shim, Ji-Eun Hong, Min-Cheol Park

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Journal of oncology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Su-Jin KangDepartment of Korean Medicine Obstetrics & Gynecology, Won-Kwang University Korean Medicine Hospital, Iksan-si.
Eun-Heui JoDepartment of Acupuncture and Moxibustion, Won-Kwang University Korean Medicine Hospital, Deokjin-gu, Jeonju-si.
Geum-Jin YangKorean Medicine Dermatology Clinical Research Center of Won-Kwang University.
Yu-Hwa ShimKorean Medicine Dermatology Clinical Research Center of Won-Kwang University.
Ji-Eun HongDepartment of Acupuncture and Moxibustion, Won-Kwang University Korean Medicine Hospital, Deokjin-gu, Jeonju-si.
Min-Cheol ParkDepartment of Korean Medicine Ophthalmology and Otolaryngology and Dermatology, Won-Kwang University Korean Medicine Hospital, Iksan-si, Jeollabuk-do, Republic of Korea.
Wonkwang University · KRDunsan Korean Medicine Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtopic dermatitis (AD) is a chronically relapsing inflammatory skin disease that affects the quality of life in patients with AD. Since there is limitation of conventional treatment of AD, complementary treatment is required to treat AD symptoms more effectively and safely Soshiho-tang (SSHT) is a traditional herbal medicine that exhibits anti-inflammatory and anti-ulcer effects and improves the immune function. In this clinical trial, we will evaluate the efficacy and safety of SSHT in patients with AD and gastrointestinal disorders in comparison with placebo. METHODS/

designThis study is a single-center, randomized, double-blind, placebo-controlled, and investigator-initiated clinical trial. A total of 60 patients aged 3 to 18 years with AD and gastrointestinal disorders and who received a diagnosis of AD by Hanifin & Rajka criteria with a Scoring Atopic Dermatitis (SCORAD) index between 15 and 49 will be enrolled. Participants will be randomly assigned to the SSHT or placebo group in a ratio of 1:1. Additionally, they will have a visit schedule comprising 4 visits including a screening visit during 8 to 10 weeks. The participants will be administered SSHT or placebo 3 times a day for 4 weeks. The primary outcome will be measured by a change of the SCORAD index. The secondary outcome measures include the following: survey questionnaires for the perception of gastrointestinal disorders, amount and frequency of ointment usage for AD, dermatology quality of life index, itchiness and sleep disability score in visual analog scale, percutaneous water loss, skin surface temperature, Hamilton anxiety rating scale, and children's depression inventory. DISCUSSION: In our knowledge, this will be the first clinical trial to assess the efficacy and safety of SSHT in patients with AD and gastrointestinal disorders. The findings of this study will provide new treatment options for patients with AD and gastrointestinal disorders.

trial registrationKorean National Clinical Trial Registry, Clinical Research Information Service. (KCT0003713) https://cris.nih.go.kr/cris/search/search_result_st01_en.jsp?seq=13489&ltype=&rtype=.

Indexed as

AdolescentChildChild, PreschoolDermatitis, AtopicDouble-Blind MethodFemaleGastrointestinal DiseasesHumansMaleOintmentsPlant ExtractsQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexTreatment OutcomeOintmentsPlant Extractssoshiho-tang

Identifiers

PMID31045830
PMCPMC6504306
OpenAlexW2943225606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.